Last trading day before full results24 May 2024 08:49
I’ve sold out, that’s my trade at 08:27. Another loss made on this share.
I didn’t have a lot invested here. I lost £3300 when I sold out at 2.55p in the back end of last year. I bought approx 200,000 shares at about 0.85p in February. I know it’s not much but I don’t want to lose it, I’m here to make money, I would like to just experiment with this money now to see if I can make it grow with short term trading on shares which release good RNS’s each day.
I bought in after the dispute notice was issued, confident that there was an oversight or some small detail which EVG overlooked to meet the requirements of the milestone payment, after all EVG had stated they expected up to $5.5m this year in milestone payments and Stalicla stated on their website that this would go into phase 2 this year.
However clearly it’s not some small oversight, 15 weeks have passed without any update or news. As DSFlat pointed out, there are no updates on the data analysis by Stalicla and even Stalicla removed from their website that this would go into phase 2 this year. Doesn’t that say it all?
Everything has been so quiet on SFX-01, so little news in the last year. TCF cannot afford to do clinical trials on their main asset and no one is signing deals to trial it for their potential own gain. Everything seems to have dried up, with not a penny of income in the last 12 months.
The acquisition of the new company even feels like they ran out of work with SFX-01 and they have had to shelve their plans.
I sold my holding but it had to go to a negotiated order, again not a good sign when you can’t get prices to sell as they did give a price to buy.
Today is the last trading day before full results, uninspiring results could see this drop further, but positive encouraging results could see this rise. But can it really be positive given the year they’ve had?
It has been a rotten year, the share price is a disaster. We thought 2p was low, now we would need to see a rise of 300% just to get there. In one of the QnA’s last year they talked about wanting to get shareholder value, well they are not doing a very good job on it.
What a disappointment this share has proved to be.